Marinus Pharmaceuticals (NASDAQ:MRNS) Earns “Overweight” Rating from Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the company. StockNews.com started coverage on Marinus Pharmaceuticals in a research note on Sunday, November 10th. They issued a “hold” rating for the company. Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Monday, September 23rd. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Down 2.2 %

Shares of MRNS opened at $0.30 on Thursday. The business has a 50-day simple moving average of $1.22 and a two-hundred day simple moving average of $1.31. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The stock has a market cap of $16.66 million, a price-to-earnings ratio of -0.12 and a beta of 1.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. Marinus Pharmaceuticals had a negative net margin of 446.48% and a negative return on equity of 7,831.35%. The company had revenue of $8.54 million during the quarter, compared to analyst estimates of $8.95 million. On average, equities analysts anticipate that Marinus Pharmaceuticals will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after purchasing an additional 1,253,901 shares during the period. Avoro Capital Advisors LLC boosted its position in Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after acquiring an additional 990,607 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares during the period. abrdn plc raised its position in shares of Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after acquiring an additional 1,578,329 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its stake in shares of Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 817,050 shares during the last quarter. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.